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Heterogeneity is a hallmark of the adaptive immune system. This is most evident in the enormous
diversity of B and T cell antigen receptors. There is also heterogeneity within antiviral T cell popula-
tions, and subsets of effector andmemory T cells nowpermeate our thinking about specialization of T
cell responses to pathogens. It has been less clear, however, how heterogeneity in developing virus-
specific effector andmemory T cells is related to cell-fate decisions in the immune response, such as
the generation long-lived memory T cells. Here we discuss recent findings that might help redefine
how heterogeneity in antiviral T cell populations gives rise to T cell subsets with short- and long-lived
cell fates.Cardinal Features of Memory T Cells
Immunological Memory (IM) is a defining characteristic of
the adaptive immune system that, during primary infec-
tion, produces long-lived plasma cells and memory T
and B cells. These memory B and T cells are endowed
with unique properties that permit more vigorous and spe-
cific responses upon reinfection to protect against patho-
gens. These key memory B and T cell properties are cen-
tral to our current understanding of IM, yet the pathways
that give rise to optimal memory B and T cells remain
poorly understood. This review will focus principally on
the development of memory T cells during viral infection.
The accompanying review by Do¨rner and Radbruch
covers recent work on antiviral B cell responses (Do¨rner
and Radbruch, 2007). Here we focus on recent advances
in our understanding of antiviral memory CD8+ T cell
differentiation and, although the majority of the discussion
focuses on viral systems, selected data from nonviral
experimental models are also discussed, where relevant
to antiviral immunity.
Over the last ten years, the innovation of major histo-
compatibility complex (MHC) class I and II tetramers, the
use of T cell receptor (TCR) transgenic mice, and other
techniques have led to the detailed quantitation, isolation,
and characterization of virus-specific T cell populations in
mice, nonhuman primates, and humans during infection.
This work outlined the kinetics of virus-specific responses
with great precision (Figure 1). A T cell response to a typical
acute viral infection can be characterized by three distinct
phases: expansion and effector T cell differentiation
(profound clonal expansion and acquisition of effector
functions), contraction (death of the majority of activated
effectors T cells via apoptosis), and stable memory (for-
mation of a numerically stable long-lived population of
memory T cells) (Ahmed and Gray, 1996; Williams and
Bevan, 2007; Zinkernagel et al., 1996). Virus-specific Tcells can expand as much as 104-fold to 105-fold, in as
little as 8 days, from as few as 100–200 naive precursors
(Arstila et al., 1999; Blattman et al., 2002). This massive
T cell proliferation is critical to long-term immunity be-
cause the magnitude of the initial clonal burst typically
determines memory T cell numbers (Hou et al., 1994;
Murali-Krishna et al., 1998). Moreover, extensive cellular
differentiation occurs as these newly activated T cells
become potent antiviral effector T cells and ultimately
memory T cells. Effector T cells migrate to virtually all
tissues and eliminate the pathogen by killing infected
cells, producing cytokines, and recruiting other leuko-
cytes via chemokine production. In general, effector
CD8+ T cells control infection through cytotoxic activity
(via perforin and granzymes) and the secretion of inter-
feron (IFN)-g and tumor necrosis factor (TNF)a (Kaech
et al., 2002b; Wherry and Ahmed, 2004; Williams and
Bevan, 2007). Effector CD4+ T cells take on a diverse set
of roles and inhibit viral replication through the production
of antiviral cytokines (and perhaps cytotoxicity), but they
also activate dendritic cells (DCs) and provide help to B
cells and CD8+ T cells (Seder and Ahmed, 2003).
After the expansion and contraction phases, a fraction
(i.e., typically 5%–20%) of virus-specific T cells survives,
forming a pool of memory T cells. Unlike most somatic
cells in which terminal differentiation results in a functional,
but a nonmitotic cell, the major product of memory T cell
differentiation is a population of T cells that retains stem
cell-like qualities. That is, after acute viral infections,
long-livedmemory T cells are endowedwithmultipotency,
a high proliferative potential, telomerase expression, and
self renewal (Williams and Bevan, 2007). These memory
T cells persist in an antigen-independent, but cytokine-
dependent (namely interleukin-15 [IL-15] and IL-7), man-
ner, and slowly divide (referred to here as homeostatic
turnover) (Surh et al., 2006). But almost immediatelyImmunity 27, September 2007 ª2007 Elsevier Inc. 393
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ReviewFigure 1. A Homogenous and
Heterogeneous View on Antiviral
Memory T Cell Development
(A) T cells clonally expand and homogeneously
differentiate into effector T cells, of which most
die, but some persist to become long-lived
memory T cells. Upon reinfection, memory T
cells re-expand and control infection faster
than 1 infection.
(B) Two populations of effector T cells form
with different memory T cell potential: short-
lived effector T cells (SLECs; yellow line) that
do not gain memory T cell potential, and mem-
ory precursor effector cells (MPECs; blue line)
that do. Upon reinfection, it is primarily the
descendents of MPECs that participate in
secondary responses because of their
enhanced proliferative capacity.upon reinfection,memory T cells begin to produce effector
molecules, undergo dramatic clonal expansion, and differ-
entiate into secondary effector T cells. This qualitatively
and quantitatively enhanced memory T cell response
results in faster control of infection compared to a pri-
mary response (Figure 1). Thus, the cardinal features of
memory Tcells aremaintenanceof (1) highproliferativepo-
tential, (2) amultipotent state,meaning thatmemory T cells
canmaintain memory T cell identity but also rapidly reacti-
vate antiviral effector functions upon reinfection, and (3)
long-term survival and self renewal in the absence of anti-
gen via IL-7- and IL-15-driven homeostatic turnover.
This fairly customary description of effector and mem-
ory T cell differentiation during viral infection, however,
does not incorporate the complexity of the multiple sub-
populations of T cells that are now known to exist. These
effector and memory T cell subsets differ not only in their
effector functions, migratory properties, and proliferative
potential, but also in their long-term persistence and abil-
ity to form protective memory T cells. How these distinct
effector and memory T cell subsets form, function, and
persist is a matter of great interest and will be the main
topic of this review.
Effector and Memory T Cell Development
and Fate Decisions
Models of Memory T Cell Development during
Viral Infection
Despite tremendous advances in our characterization of
memory T cells in the last decade, we still do not know
when and how memory T cells actually form after infec-
tion. The answers might largely depend on how one
defines a memory T cell. One of the oldest but still most
widely used definitions is based simply on time after in-
fection; once antigen-specific T cell numbers stabilized
(several weeks to months after infection), these cells
were typically deemed memory T cells. However, this
definition does not take into account the more concrete
functional aspects and subsets of memory T cells
described above. When considering the development of
T cell memory on the basis of measurable memory T cell394 Immunity 27, September 2007 ª2007 Elsevier Inc.properties (i.e., high proliferative potential, multipotency,
rapid recall, and homeostatic turnover), at least four pos-
sible models can be envisioned (Figure 2).
Model 1—Uniform Potential. The first model is rooted in
an extrinsic viewpoint. Here, the effector T cell pool is rela-
tively homogenous, with each cell having acquired effector
functions and memory T cell developmental potential
equivalently. Competition for, orwithdrawal from, nutrients,
cytokines, growth factors, antigen, or other environmental
resources limits the number of T cells that can survive con-
traction and enter the memory T cell pool (Freitas and
Rocha, 2000). However, this simple model of memory T
cell formation is insufficient to explain the heterogeneity
within effector and memory T cell populations and also
does not help define when memory T cell properties are
acquired.
Model 2—Decreasing Potential. In the second model,
the early effector T cells also start off with relatively equal
memory T cell developmental potential. However, the ef-
fector T cells progressively lose memory cell potential
and are pushed toward terminal differentiation in a linear
fashion as TCR stimulation is increased or prolonged
(Ahmed and Gray, 1996). This second model provides
a mechanism for creating a heterogeneous pool of effec-
tor T cells in various stages of differentiation according
to their stimulation history during infection. This model
might be particularly useful in explaining the properties
of latecomers in the T cell response (Catron et al., 2006;
D’Souza and Hedrick, 2006; Jelley-Gibbs et al., 2007)
and T cell fates during chronic or latent infections or repet-
itive stimulation (Wherry and Ahmed, 2004). Although this
model was originally based mostly on the effects of anti-
genic signaling, it does not rule out that exposure to other
signals might be involved.
Model 3—Fixed Lineage. A third model posits that
memory or effector T cell lineage commitment occurs
very early after the initial T cell stimulation, such that fully
mature memory T cells and effector T cells coexist within
the effector T cell population (Farber, 1998; Sallusto and
Lanzavecchia, 2001). According to this model, these
preformed memory T cells might bypass the effector
Immunity
ReviewFigure 2. Models of Effector and
Memory Cell-Fate Decisions during
Acute Viral Infection
Model 1—uniform potential. All activated
effector cells develop equal potential to be-
come MPECs (aqua cells), but extrinsic factors
limit the number of memory T cells generated.
MPECs give rise to transitional TEM cells (gray)
that convert into self-renewing TCM cells (dark
blue).
Model 2—decreasing potential. Shorter
durations of antigenic stimulation favor MPECs
that give rise to TCM cells. Longer stimulation
promotes terminal differentiation of SLECs
(yellow) and end-stage TEM cells (green) that
decline over time.
Model 3—fixed lineage. Upon activation, naive
T cells develop into either SLECs or fully ma-
ture memory T cells. In this model, cells might
bypass an effector stage and develop directly
into self-renewing TCM.
Model 4—fate commitment with progressive
differentiation. According to the strength of sig-
nal, either an MPEC or SLEC fate will
be adopted early after activation. The MPECs
acquire effector functions, but remain multipo-
tent (e.g., can still become memory T cells or
SLECs). Most SLECs die, but some persist
with a limited lifespan as an end-stage TEM
cell. MPECs survive, and give rise to transi-
tional TEM cells that progressively mature into
long-lived TCM cells.stage, possess all characteristic traits of memory T cells,
and survive the contraction phase, whereas the effector
T cells die. Some evidence for this model is that at the
peak of clonal expansion, a minority of T cells bears phe-
notypic resemblance to memory T cells found several
weeks later (Lefrancois and Marzo, 2006). Also, it is possi-
ble to isolate CD4+ T cells early in the immune response
that do not have full effector function, but can persist
long term (Wu et al., 2002). Furthermore, this model might
more accurately portray the events that occur when naive
T cells are primed under noninfectious conditions, such as
with DC vaccines (Badovinac et al., 2005). In another re-
cent study, asymmetric separation of daughter cells at
the first T cell division was observed, and one daughter
T cell adopted amemory cell fate and the other an effector
T cell fate (Chang et al., 2007), suggesting that lineages
might be fixed as early as the first cell division. It remains
to be determined, though, how this 50:50 split in cell fates
after division one leads to only 5%–20%of the clonal T cell
burst entering the memory T cell pool.
Model 4—Fate Commitment with Progressive Differen-
tiation. The fourth model builds on the first three, but dif-
fers in several important respects. One distinction is that
it postulates the existence of memory precursor effector
cells (MPECs). These MPECs are not fully mature memory
T cells, as in the third model, but rather they possess
effector properties (hence MPEC) and require furtherdifferentiation to gain quintessential memory T cell proper-
ties, such as a high proliferative potential and the ability to
undergo homeostatic turnover. Also, the effector T cell
pool is heterogeneous and contains many short-lived
effector cells (SLECs) that will die after infection, and
a smaller fraction of MPECs with the potential to become
long-lived memory T cells. The SLECs are a terminally
differentiated cell population, but, unlike in the third
model, the MPEC fate is not fixed. That is, the MPECs
retain plasticity to develop into SLECs if additional strong
stimulatory signals are encountered (e.g., persisting anti-
gen and/or inflammation). This model is also consistent
with early fate commitment in the first T cell division
(Chang et al., 2007) if the memory-fated daughter T cells
require further differentiation events to mature into
a long-lived memory T cell.
In this model, the primary basis for the cell-fate decision
is the magnitude of the overall strength of signal, which
includes the combined effects of antigen, costimulation,
and inflammation (signals 1, 2, and 3). High or excessively
strong signals drive greater clonal expansion but also pro-
mote terminal effector T cell differentiation. The fourth
model differs from the decreasing-potential hypothesis
in that different cell fates can be specified early according
to the intensity of the signals received (Gett et al., 2003)
but do not require multiple rounds of stimulation to create
heterogeneous cell fates.Immunity 27, September 2007 ª2007 Elsevier Inc. 395
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ReviewTable 1. Characteristics of T Cells Responding to Different Types of Viral Infections
Type of Infection Phenotype of T Cells Functional Properties Examples of Infections
Acute viral Infection (Memory Phase)
CD62LHi > CD62LLo –High proliferative potential LCMV (Acute Strains)
CD44Hi –Potent effector functions (IFN-g, TNF-a, IL-2, cytotoxicity) VSV
CD27Int/Hi –Potent homeostatic turnover Vaccinia virus











CD62LLo > CD62LHi –Intermediate proliferative potential gHV
CD44Hi –Weaker effector
functions (lower IFN-g, TNF-a, IL-2)
EBV










CD62LLo –Low proliferative potential LCMV (chronic strains)
CD27Lo/Int –Poor effector functions (exhausted) HCV
CD44Hi –Little or no homeostatic turnover HIV







CD69HiDistinguishing which of the models of memory T cell
development occurs during viral infections has been a
difficult and controversial challenge. Indeed, these
models are not mutually exclusive, and it is possible that396 Immunity 27, September 2007 ª2007 Elsevier Inc.multiple pathways exist for generating effector T cells
and long-lived memory T cells depending on the T cell
priming conditions. We will now discuss our current un-
derstanding of effector and memory T cell heterogeneity
Immunity
ReviewFigure 3. Differential Effects of Acute,
Latent or Chronic Viral Infections on
Memory T Cell Differentiation
Viral infections fall into three categories based
on the duration and pattern of viral infection—
(1) acute, (2) latent with reactivation, and (3)
chronic or persistent.
Primary acute infection generates SLECs (yel-
low) and MPECs (aqua). For a description of
the cell types, see Figure 2. The majority of
SLECs die, but some persist for finite intervals
(TEM cells; green). In contrast, MPECs survive
and progressively mature from transitional
TEM cells (light blue) into protective TCM cells
(dark blue).
During latent or reactivating viral infections,
a mixed population with a variety of effector
and memory differentiate states is formed.
Typically, there will be more SLECs and TEM
cells than after acute infection. The abundance
of secondary MPECs, resting TCM cells, or
transitional TEM cells will likely depend on the
frequency and degree of viral reactivation.
During persistent or chronic viral infections,
with high viremia, T cells can undergo altered
differentiation and become exhausted (red).
According to the type of infection, the snap-
shot of effector and memory T cells present
(outlined in red box) is likely to be different.
See Table 1 for detailed descriptions of com-
mon attributes.and the implications for T cell memory with these models
as a guide.
Identification of Memory Precursors and Defining
Their Progressive Differentiation
Initially, several reports suggested that the entire Naive/
Effector/Memory (N/ E/M) differentiation process
could run on autopilot after a brief (24 hr) stimulation with
antigen (Williams and Bevan, 2007). Subsequent work has
shown that CD4+ T cell help, IL-2, inflammation, and per-
sisting antigen can greatly influence memory T cell differ-
entiation. Moreover, functional, phenotypic and gene-
expression profiling of antigen-specific T cell populations
during the course of an antiviral T cell response has led to
the notion that fully competent memory T cells develop
gradually after the clearance of acute viral infection (as re-
ferred to in models 1 and 4) (Kaech et al., 2002a). After
most acute viral infections, the memory T cell pool slowly
converts from a population containing mostly effector
memory T (TEM) cells (e.g., CD62L
Lo, CCR7Lo, IL-2Lo) to
one containing central memory T (TCM) cells (e.g.,
CD62LHi, CCR7Hi, IL-2+) that exhibit a high proliferative
potential and can homeostatically turn over (Wherry and
Ahmed, 2004). A number of other important phenotypic
changes also occur gradually in the memory pool, result-
ing in memory T cells with a more mature phenotype (IL-
7RHi, CD27Hi, CD122Hi, Bcl-2Hi, KLRG1Lo, CXCR3Hi, and
CD43Lo) that differs considerably from the starting effector
T cell population (Figure 3 and Table 1) (Badovinac et al.,
2007; Hikono et al., 2007; Kaech et al., 2003; Wherry
et al., 2004; Wherry et al., 2003). Because this process isgradual, a snapshot taken at one or two time points early
after infection might be insufficient to appreciate the full
dynamics and timeframe of these changes. The pheno-
typic changes in thememory T cell population could result
from selective survival of different subsets (model 3),
actual cellular conversion (models 1 and 4), or both.
The progressive changes in memory T cell function
(e.g., high proliferative potential, homeostatic turnover)
that accompany the E / M transition help to delineate
when memory T cells form after acute infection. These
data alone, however, do not distinguish whether the effec-
tor T cell population is homogenous or heterogeneous
with regard to the potential to form memory T cells (model
1 versus models 2, 3, and 4). The examination of gene and
surfacemarker expression has demonstrated that, like the
memory T cell population, the effector T cell population is
rich in cellular and functional heterogeneity (Wherry and
Ahmed, 2004). In particular, a subset of effector CD8+ T
cells can be identified that already expressed certain fea-
tures of memory CD8+ T cells, such as increased IL-7R
expression (Huster et al., 2004; Kaech et al., 2003). How-
ever, these IL-7RHi effector CD8+ T cells did not appear to
be preformed memory T cells (model 3), but rather they
were more like MPECs (model 4). The IL-7RHi T cells had
full effector function and expressed cytotoxic molecules
(e.g., granzyme B) and IFN-g, but, similar to their IL-7RLo
counterparts, the IL-7RHi effector T cells had a relatively
low proliferative capacity compared to mature memory
T cells (Huster et al., 2004; Kaech et al., 2003). The IL-
7RHi effector T cells, however, had a substantiallyImmunity 27, September 2007 ª2007 Elsevier Inc. 397
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compared to the IL-7RLo effector T cells (Huster et al.,
2004; Kaech et al., 2003). A number of subsequent studies
in infectious models support the idea that the IL-7RHi frac-
tion of effector CD8+ T cells contains MPECs, though in
some cases (e.g., low inflammatory conditions), not all
IL-7RHi effector T cells are destined to populate the mem-
ory pool (Castellino and Germain, 2007; Hand et al., 2007;
Huster et al., 2004; Kaech et al., 2003; Lacombe et al.,
2005). Taken together, it appears that by approximately
1 to 2 weeks after viral infection, effector CD8+ T cells
have committed to short-lived or long-lived cell fates.
Pathways That Induce Effector and Memory
T Cell Heterogeneity
What are the signals and genetic pathways that affect T
cell longevity and specify different effector and memory
T cell lineages? Although we are far from a complete un-
derstanding of these pathways, a substantial body of
work has outlined some key factors, including (1) the
role of CD4+ T cell help , (2) common gamma-chain cyto-
kines, and (3) the strength of antigenic and inflammatory
signals during T cell priming.
CD4+ T Cell Help and IL-2
CD4+ T cells, CD40-CD40L signals, and IL-2 help to max-
imize effector CD8+ T cell expansion, an effective E/ M
transition, and long-term maintenance after acute viral in-
fections (Northrop and Shen, 2004; Rocha and Tanchot,
2004; Williams and Bevan, 2007). The result of defective
CD4+ T cell help is the generation of a population of anti-
viral CD8+ T cells that largely resembles TEM cells, re-
sponds poorly to rechallenge, and in some cases ex-
presses the death receptor, Trail (Badovinac et al., 2006;
Janssen et al., 2005). Interestingly, IL-2 acts early during
infection to instill robust recall capacity in the memory
CD8+ T cells that develop later (Williams et al., 2006). An
early source of IL-2 during CD4+ T cell priming is also
required for optimal memory CD4+ T cell differentiation
(Dooms et al., 2007). One possible mechanism for early
CD4+ T cell help for CD8+ T cells is by the enhancement
of naive CD8+ T cell chemotaxis to helped DCs (Castellino
et al., 2006). In addition, there is some evidence that the
high-affinity antibodies produced by the CD4+ T:B cell col-
laboration may indirectly help memory CD8+ T cell devel-
opment because passive immune therapy can improve
memory CD8+ T cell function in CD4+-deficient animals
(Bachmann et al., 2004). Theremight also be an interesting
connection between elevated T-bet expression in un-
helped CD8+ T cells and the enrichment of TEM-phenotype
cells. (Intlekofer et al., 2007) Thus, CD4+ T cells appear to
modulate the developing effector and memory T cell sub-
populations throughmechanisms that include APC activa-
tion, CD40:CD40L, IL-2, neutralizing antibody, Trail, and
T-bet.
IL- 7 and IL-15
IL-7 and IL-15 are important for both antiviral memory
CD8+ and CD4+ T cell generation and homeostasis (Pur-
ton et al., 2007; Surh et al., 2006). In vitro priming in the
presence of IL-2 or IL-15 can lead to TEM cell-like or TCM398 Immunity 27, September 2007 ª2007 Elsevier Inc.cell-like populations of CD8+ T cells, respectively (Manju-
nath et al., 2001). IL-7 and IL-15, however, do not appear
to play major instructive roles in the actual MPEC- versus
SLEC-fate decision in vivo. Most data indicate that reduc-
ing or enhancing IL-7 or IL-15 signals during the N/ E or
E/ M stages does not greatly alter the number IL-7RHi
MPECs or memory CD8+ T cells that ultimately form
(Hand et al., 2007; Klonowski et al., 2006; Sun et al.,
2006; Tripathi et al., 2007) (S.M.K., unpublished data).
Treatment with IL-2, IL-7, and IL-15 during the contraction
phase will substantially protract effector T cell death, but it
does not seem to affect the memory CD8+ T cell popula-
tion quantitatively or qualitatively (Blattman et al., 2003;
Hand et al., 2007; Klonowski et al., 2006; Melchionda
et al., 2005; Sun et al., 2006; Tripathi et al., 2007)
(S.M.K., unpublished data). Moreover, the forced expres-
sion of IL-7R on all effector CD8+ T cells does not save the
terminally differentiated IL-7RLo SLECs from death (Hand
et al., 2007). Altogether, these data suggest that IL-7R
downregulation is symptomatic, not causal, to effector
CD8+ T cell contraction after infection and that, although
IL-7 and IL-15 can clearly provide survival signals, these
important homeostatic cytokines are unlikely to provide
differentiation signals for the generation of subsets of
effector and memory T cells in vivo.
Strength of Signal: Antigen, Costimulation,
and Inflammation
In general, there are three major classes of signals neces-
sary for T cell activation and differentiation: signal 1 from
antigen, signal 2 from costimulation, and signal 3 from in-
flammation. The strength (magnitude and/or duration) of
signal 1 can influence the size of the virus-specific T cell
response (Bullock et al., 2000; Wherry et al., 1998; Wherry
et al., 1999). What has remained less clear is how the
strength of TCR signaling during infection qualitatively
influences memory T cell differentiation. Limiting the
strength or duration of signals received by T cells during
priming can alter both the types of effector T cell subsets
produced and their rate of memory cell maturation. In gen-
eral, blunting the infection, reducing the duration of stimu-
lation, or increasing intraclonal T cell competition leads to
enhanced formation of effector T cells expressing high
amounts of IL-7R and CD62L and low amounts of
KLRG1 (Badovinac et al., 2007; Badovinac et al., 2005;
Joshi et al., 2007; Marzo et al., 2005; Williams and Bevan,
2004) (E.J.W., unpublished data). In some experiments,
this effect was accompanied by more rapid, but not
necessarily more abundant, memory T cell development
(Badovinac and Harty, 2007; Badovinac et al., 2005). To-
gether, these observations demonstrated that the
strength or duration of infection is a critical factor regulat-
ing the quality and rate of memory CD8+ T cell differen-
tiation, but it was unclear how the strength of antigenic,
costimulatory, or inflammatory signals was individually
involved.
Costimulatory signals (signal 2) from receptors such
as CD28, CD40, 41BB, CD27, ICOS, and OX40 clearly im-
pact the size of the antiviral effector and memory T cell
populations, with some notable differences in their effects
Immunity
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Watts, 2005). Interestingly, the expression levels of some
costimulatory receptors, including CD27, CD28, and
others, are often used to distinguish subsets of antiviral
T cells, especially in humans (van Lier et al., 2003). Costi-
mulation certainly plays an important role in effector and
memory T cell survival during infection, but what influence
these signals have, if any, on instructing effector versus
memory T cell-fate determination is not clear.
Although inflammation can augment the expression of
costimulatory molecules, inflammatory cytokines can also
directly impact effector T cell expansion and differenti-
ation (Mescher et al., 2006). For example, type I IFN, IL-
12, and IFN-g signals can act directly on T cells for optimal
effector T cell expansion and survival (Badovinac et al.,
2000; Curtsinger et al., 2003; Haring et al., 2005; Kolumam
et al., 2005; Mullen et al., 2001; Whitmire et al., 2005a;
Whitmire et al., 2005b). An interesting point that emerged
from these studies is that the nature of the pathogen can
determine which cytokine will bemost influential for devel-
oping effector T cells (Cousens et al., 1999). For instance,
lymphocytic choriomeningitis virus (LCMV) specific CD8+
T cell responses are critically dependent on type I IFN,
but do not require IL-12, whereas the opposite is true for
CD8+ T cells responding to Listeria monocytogenes infec-
tion (Way et al., 2007).
Inflammatory cytokines also appear to play a key role in
some cell-fate decisions in the developing T cell response
by altering the distribution of effector T cells that have
memory T cell potential (i.e., MPECs) versus terminally dif-
ferentiated cells (i.e., SLECs) (Badovinac et al., 2005;
Joshi et al., 2007; Pearce and Shen, 2007). Under low in-
flammatory conditions, fewer IL-7RLo effector T cells are
generated. As inflammation increases, the formation of
more IL-7RLo effector T cells is favored. It appears that
for a constant dose of antigen, increasing inflammatory
signals can increase the SLEC to MPEC ratio. IL-12 and
IFN-g are two primary players in this process, but other
signals are undoubtedly involved in this process because
IL-12 and IFN-g amounts can vary between different infec-
tions (Cousens et al., 1999), and likely candidates are type
I IFNs (Curtsinger et al., 2005; Kolumam et al., 2005; Way
et al., 2007), other IL-12 family members, or even Toll-like
receptor ligands that act directly on T cells (Hervas-
Stubbs et al., 2007). For the purposes of vaccination,
one might predict that the type of inflammatory signal
will be as important as the amount. Indeed, some recent
evidence for this concept is emerging from vaccine stud-
ies (Wille-Reece et al., 2006), and this issue of the recog-
nition of viral infection by the innate immune system and
subsequent inflammatory response is covered in the ac-
companying review by Pichlmair and Reis e Sousa (2007).
Although a dose-dependent inflammation model sug-
gests that for a given dose of antigen lower inflammatory
conditions favor memory T cell development, this should
not be incorrectly interpreted to mean that the absence
of inflammation enhances memory T cell formation. The
priming of T cells without any inflammation leads to toler-
ance and/or clonal deletion (Redmond and Sherman,2005). Thus, some inflammation is clearly required for
optimal T cell expansion, effector T cell development,
and memory T cell generation. It is not clear, however,
whether increased inflammation would induce greater
numbers of SLECs at the expense of MPECs or whether
MPEC numbers are determined by other factors. More-
over, if the SLEC versus MPEC decision is based on an
overall strength of signal, then the effects of inflammation
might vary according to the degree of TCR stimulation.
This idea should be testable by varying inflammation at
constant doses of antigen and vice versa, and then exam-
ining SLEC versus MPEC fates and memory T cell forma-
tion. In addition, it will be interesting to examine whether
inflammation can act in a bystander manner with or with-
out TCR signaling during memory T cell differentiation. To
rationally apply these principles to vaccination, one might
need to determine the optimal inflammatory signals for
a given dose or regimen of antigen exposure.
Balancing Effector T Cell Differentiation
and Memory T Cell Fates
Additional heterogeneity, other than simply short-term
and long-term fates, exists in the functional specification
of T cells during infection. This point is more obvious for
CD4+ T cells, compared to CD8+ T cells, where a diverse
array of effector cell types (Th1, Th2, Th17, TFH, Treg,
etc.) exists. Thus, T cell fate decisionsmight exist in layers:
Activated T cells commit to (1) which type of effector cell to
become and (2) whether to be long lived or not. The spec-
ification of different effector CD4+ T cell populations is
based on key innate immune cytokines that induce the ap-
propriate effector T cell response for the given pathogen
or adjuvant (IFN-g and IL-12 / T-bet / Th1; IL-4 /
GATA3 and c-maf / Th2; IL-6 and TGFb / rorg /
TH17 and TGFb/ FoxP3/ Treg). It is unclear whether
every effector T cell lineage produces long-lived, self-
renewing memory T cells, and if so, whether common or
separate pathways are used. For example, some evi-
dence implies that IL-7R might also be a marker for Th1
CD4+ T cells (Dooms et al., 2007; Kondrack et al., 2003;
Li et al., 2003; Purton et al., 2007), but it remains to be
seen whether this will apply to all effector T cell lineages
(e.g., Th2 or Th17).
Some data suggest that effector function specification
and memory T cell potential are intertwined, but the pre-
cise mechanism is unclear (Intlekofer et al., 2005; Joshi
et al., 2007; Takemoto et al., 2006;Wu et al., 2002). For ex-
ample, Th1 cells with the potential to form memory T cells
versus terminally differentiated effector Th1 could be dis-
tinguished based on low and high levels of IFN-g produc-
tion, respectively (Wu et al., 2002). It is worth pointing out
that virus-specific IFN-g-producing CD4+ T cells can effi-
ciently populate the memory T cell pool (Whitmire et al.,
2006), though the attrition of these cells has been docu-
mented in some infections (Homann et al., 2001). Another
example is that recent work in CD8+ T cells suggests that
memory T cell potential is inversely linked to T-bet expres-
sion. In LCMV infection, SLECs contain higher amounts of
T-bet than do MPECs, and the overexpression of T-bet inImmunity 27, September 2007 ª2007 Elsevier Inc. 399
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(Joshi et al., 2007). T-bet expression can be regulated
by inflammatory cytokines in a dose-dependent manner,
and hence these data provide a mechanism for how
some inflammatory signals can influence the MPEC- ver-
sus SLEC-fate decision (Joshi et al., 2007; Takemoto
et al., 2006). Also, it is not clear how T-bet and eomeso-
dermin (Eomes), another T-box transcription factor in-
volved in effector CD8+ T cell differentiation, cooperate
to regulate effector CD8+ T cell fates (Takemoto et al.,
2006).
The control of innate cytokines on T cell expression of
lineage-determining transcription factors, such as T-bet,
that can specify both effector functions and memory
fates creates a sensible way for the innate immune sys-
tem to influence T cell homeostasis long term. It will be
interesting to examine whether this model applies to
other key transcription factors involved in lymphocyte
differentiation.
Memory T Cell Subsets
T cell heterogeneity also has considerable implications for
the protective immunity afforded by memory T cells. In-
deed, it was the seminal work of a few groups in the late
1990s that first outlined the existence of specific memory
T cell subsets (coined TEM and TCM cells) and alerted us to
the importance of heterogeneity within antigen-specific
T cell populations (Hamann et al., 1997; Sallusto et al.,
1999). However, it is quite evident today that memory T
cell heterogeneity is more complex than simply TCM and
TEM cells. Nonetheless, the concept of TEM and TCM cells
remains an important paradigm, though a number of
important questions remain unresolved with regard to
thesememory Tcell subsets. These includeunderstanding
howTEMandTCMcells contribute to protective immunity to
different pathogens, the precise lineage relationships
between these cell types, and how the heterogeneity in
the memory T cell pool is related to the early effector
T cell heterogeneity discussed above.
TEM and TCM cells were first distinguished in humans
based on lymph node (LN) homing receptor CD62L and
CCR7 expression, effector functions, and proliferative
capacity (Sallusto et al., 1999). These studies gave rise
to the original views of TEM and TCM cells in which TEM cells
exist at the portals of pathogen entry and possess imme-
diate effector functions and a reduced proliferative capac-
ity, and TCM cells exist mainly in lymph nodes, express
effector function upon restimulation, and mount robust
secondary responses. Although these largely accepted
definitions persist, it is worth noting that one important ca-
veat of using strictly CD62LLo and CCR7Lo to define TEM
cells is that recently activated effector T cells share this
phenotype, thus blurring the line between true effector T
cells and resting TEM cells. In general, TEM cells are not
in LNs, but they can be found in spleen, blood, and a vari-
ety of nonlymphoid tissues, whereas TCM cells are found in
LN, spleen, and blood, and they also enter nonlymphoid
tissues, albeit less efficiently than do TEM cells (Marshall
et al., 2001; Masopust et al., 2001; Reinhardt et al.,400 Immunity 27, September 2007 ª2007 Elsevier Inc.2001; Wherry et al., 2003). In addition, some of the func-
tional differences first noted in CD4+ TEM and TCM cells
do not hold up as well in memory CD8+ T cell subsets be-
cause CD8+ TEM and TCM cells are nearly equivalent in
their production of effector cytokines and cytotoxicity
(Barber et al., 2003; Ravkov et al., 2003; Unsoeld et al.,
2002; Wherry et al., 2003). However, the augmented
capacity of TCM cells to proliferate to antigen and homeo-
static signals and to produce IL-2, compared to TEM cells
has held true in most analyses (Wherry and Ahmed, 2004).
The ability of TCM cells to undergo homeostatic turnover in
response to IL-7 and IL-15 is a key factor in the longevity of
these memory T cells.
Lineage Development of Memory T Cell Subsets
and Relationship to Early Effector Heterogeneity
There is ongoing debate about the development and line-
age relationship of memory T cell subsets. Some studies
suggest that TCM and TEM cells are fixed populations
that do not convert over time (Manjunath et al., 2001;
Marzo et al., 2005; Sallusto and Lanzavecchia, 2001)
(model 3), whereas others propose that TEM cells can con-
vert to TCM cells in the absence of antigen (Badovinac
et al., 2007; Bouneaud et al., 2005; Wherry et al., 2004;
Wherry et al., 2003; Zaph et al., 2006) (model 4). On the ba-
sis of recent work, we propose that after acute viral infec-
tion, there are at least three distinct T cell populations in
the early memory T cell pool. First, there exist TEM cells
derived from IL-7RHi MPECs that represent a transitional
or convertible T cell population, which can further differen-
tiate and transform slowly into TCM cells (Badovinac et al.,
2007; Marzo et al., 2005; Wherry et al., 2004; Wherry et al.,
2003) (E.J.W., unpublished data). Second, there is a popu-
lation of TCM cells primarily derived from these convertible
TEM cells. These memory T cells have acquired the ability
to efficiently self renew via homeostatic turnover (Wherry
et al., 2004; Wherry et al., 2003) (E.J.W., unpublished
data). Some TCM cells might descend directly from
CD62LHi MPECs present at the peak of clonal expansion.
Whether TCM cells that arise as a result of conversion from
TEM cells are functionally equivalent to TCM cells derived
from CD62LHi MPEC is unclear. Third, there remain
some terminally differentiated IL-7RLo KLRG1Hi CD62LLo
SLECs that can enter the memory phase and downregu-
late markers of effector activation (e.g., granzyme B).
These resting SLECs in the memory pool, however, do
not efficiently persist long term, self renew, or undergo
conversion to TCM cells (Joshi et al., 2007) (E.J.W., unpub-
lished data). These resting SLECs seem to represent an
end-stage TEM cell population.
The segregation of thememory T cells into self-renewing
TCM cells, transitional TEM cells, and end-stage TEM cells
fits with a number of experimental observations and might
help to explain some apparently disparate results in the
field. For instance, such a model helps to account for the
differences in phenotypic heterogeneity andprotective im-
munity in TEM cell subsets across different studies (Bach-
mann et al., 2005a; Bachmann et al., 2005b; Huster
et al., 2006; Roberts et al., 2005; Roberts and Woodland,
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fering proportions of transitional, end-stage TEM cells, de-
pending on the infection and time of analysis. Lastly, re-
ducing the overall strength of T cell stimulation by
increasing naive CD8+ T cell precursor frequency and T
cell competition appears to enrich the development of
transitional TEM cells (Badovinac et al., 2007) (E.J.W., un-
published data), increasing the evidence that these T cells
occupy a particular stage of memory T cell differentiation.
Protective Immunity
One of the major implications of memory T cell subsets
with different functional properties or anatomical localiza-
tion is for protective immunity. Relatively few studies,
however, have directly compared the protective capacity
of TCM and TEM cells. Mouse studies demonstrated that
CD8+ TCM cells conferred greater protective immunity
compared to TEM cells after systemic, local, and respira-
tory challenge infections, and this was associated with
a greater proliferative burst of TCM cell-derived secondary
effector T cells (Wherry et al., 2003). Evidence is accumu-
lating that TCM cells also correlate with more favorable
responses against simian immunodeficiency virus (SIV)
and human immunodeficiency virus (HIV) (Seaman et al.,
2004; Vaccari et al., 2005) and protect better against tu-
mors (Klebanoff et al., 2005). A recent study delineated
multiple memory CD8+ T cell subsets to Sendai virus
that do not conform to the strict TEM and TCM cell defini-
tions. With additional phenotypic markers, including
CXCR3, CD27, CD43 (high MW form), and KLRG1, a hier-
archical series of subsets was described with varying
degrees of recall potency (Hikono et al., 2007). However,
other studies using respiratory viruses found interesting
kinetics in which TEM cells responded better than did
TCM cells at early time points after infection, but in which
at later time points, TCM cells mounted the more vigorous
secondary responses (Roberts et al., 2005; Roberts and
Woodland, 2004), perhaps consistent with the gradual
change in the composition of transitional versus end-
stage TEM cells over time.
There might be an advantage to maintaining end-stage
TEM cells for finite lengths of time after viral clearance be-
cause this is the most likely period for reinfection to occur.
Indeed, immunity to respiratory Sendai virus or influenza
virus infection correlates best with the persistence of
TEM cells in the lungs (Hogan et al., 2001; Liang et al.,
1994). However, if the end-stage TEM cells gradually
disappear, the host could still be protected for longer
periods by transitional TEM cells that have become TCM
cells. It is interesting to consider whether functional, but
relatively senescent, TEM cells are not preferentially main-
tained in the lung and intestinal mucosa to optimally bal-
ance immunological protection and immunopathological
damage to delicate mucosal tissues.
Altered Memory T Cell Differentiation during
Repetitive or Chronic Infections
Although the above discussion of memory T cell develop-
ment pertains mostly to events occurring during primaryinfection with viruses that are completely cleared from
the host, there are several situations in which memory T
cell differentiation might differ. First, recent work indicates
that secondary (2) and tertiary (3) memory CD8+ T cells
are distinct from primary (1) memory T cells. More 2
and 3 memory CD8+ T cells persist in a CD62LLo state,
with heightened levels of granzyme B and cytotoxicity,
for longer periods of time compared to the 1 memory T
cells (Jabbari and Harty, 2006; Masopust et al., 2006). In
addition, although a substantially larger number of virus-
specific T cells can be generated with repeated infection,
the E/ M transition appears extended, and longer time
might be needed to reach stable memory T cell numbers
(Grayson et al., 2002;Masopust et al., 2006). These obser-
vations point out that memory T cell phenotype, function,
andmaintenance can be influenced by stimulation history,
and special consideration should be given to this issue
when developing prime-boost regimens for vaccination.
A second situation that can dramatically alter memory
CD8+ T cell differentiation is persisting infection (Klener-
man and Hill, 2005; Wherry and Ahmed, 2004) (Figure 3
and Table 1). A substantial body of literature exists on
the defects in T cell effector functions that can occur dur-
ing chronic infections with hierarchical loss in proliferative
capacity, cytotoxicity, and the ability to produce cytokines
(Lieberman et al., 2001; Shin and Wherry, 2007) and the
topic of chronic HIV infection is covered in the accompa-
nying review by Deeks and Walker (2007). Virus-specific
CD8+ T cells that persist during chronic infection are quite
different from memory T cells found after acute infection.
For example, during chronic viral infection, virus-specific
T cells remain CD62LLo CCR7Lo, and TCM cells rarely
develop (Wherry et al., 2004). These T cells also have
a low proliferative capacity, express low amounts of IL-7
and IL-15 receptors, and fail to respond efficiently to these
cytokines (Shin and Wherry, 2007). Rather, long-term
maintenance of virus-specific CD8+ T cells during chronic
infection depends on periodic bursts of cell division due to
persisting antigen (Shin et al., 2007) and, in some cases,
the priming of new thymic emigrants (Vezys et al., 2006).
The precise details of impaired memory T cell develop-
ment could differ depending on the whether T cells are
subjected to repetitive stimulation, for example by herpes
virus infections, or protracted, continuous stimulation
(e.g., LCMV, HIV, hepatitis C virus [HCV]).
In addition to the changes in memory T cell differentia-
tion and homeostasis, virus-specific CD8+ T cells can
become exhausted and lose effector functions during
chronic infection (Shin and Wherry, 2007). The inhibitory
receptor PD-1 is highly expressed during many chronic
infections and blockade of the PD-1-PD-L1 pathway can
restore function in these exhausted T cells (Barber et al.,
2006; Day et al., 2006; Petrovas et al., 2006; Radziewicz
et al., 2006; Trautmann et al., 2006; Zhang et al., 2007).
The extent of PD-1 expression and functional exhaustion
in a virus-specific T cells likely depends on the degree of
ongoing viral replication, antigen abundance, and inflam-
mation associated with, as well as the anatomical location
or cellular tropism of, the persisting virus. Moreover, T cellImmunity 27, September 2007 ª2007 Elsevier Inc. 401
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of a mixture of various phenotypes and functional states
(i.e., activated versus resting) depending on their recent
or history of exposure to antigen, inflammation, and other
factors (Figure 3 and Table 1).
Memory T Cell Differentiation in Humans
The above issues are particularly relevant for studying
virus-specific T cell populations in humans, and T cell phe-
notype and function often varies for different pathogens
(van Lier et al., 2003). For example, influenza virus (flu)-,
respiratory syncytial virus (RSV)-, and vaccinia virus
(VV)-specific memory CD8+ T cells, all infections that do
not persist, are usually IL-7RHi, CD62LHi, and CD27Hi
(van Leeuwen et al., 2005). In contrast, a greater propor-
tion of IL-7RLo, CD62LLo, and CD27Hi/Int cells are found
in Epstein-Barr virus (EBV)- and cytomegalovirus (CMV)-
specific CD8+ T cell populations (Boutboul et al., 2005;
van Leeuwen et al., 2005; Wherry et al., 2006). Further,
HIV-specific CD8+ T cells are mainly IL-7RLo CD62LLo,
but they express high amounts of CD27 (Appay et al.,
2002; Boutboul et al., 2005; Champagne et al., 2001;
Paiardini et al., 2005; Sabbaj et al., 2007; van Leeuwen
et al., 2005; Wherry et al., 2006). Overall, the parallels be-
tween humans and mice are striking. For example, human
memory T cells from acute infections (e.g., flu and RSV)
respond substantially better to IL-7 and IL-15 compared
to those from latent infections (e.g., EBV and CMV) (van
Leeuwen et al., 2005). Thus, pathogen persistence for
chronic, highly replicating, as well as latent, reactivating
viruses, can substantially impact human memory T cell
differentiation. It is important to keep in mind the effects
of persistent and latent viral infections on the phenotypic
heterogeneity of antiviral T cells in humans, especially
when performing cross-sectional rather than longitudinal
types of studies (Figure 3 and Table 1).
Conclusions and Implications for Vaccines
and Long-Term Antiviral Immunity
Understanding the pathways that lead to optimal genera-
tion and maintenance of memory T cells is of consider-
able importance for both prophylactic and therapeutic
vaccines. One would like to define the subsets of T cells
that will provide the most robust protective immunity for
different types of pathogens and also those capable of
persisting independent of repetitive or continual boosting.
Defining how the diversity in phenotype and function of
effector andmemory T cells arises during primary immune
responses will likely lead to the discovery of multiple sig-
nals and pathways that control the differentiation of T cells
with different functions, protective capacities, and long-
term fates. Decoding the pathways and molecules that
can be used to therapeutically enhance long-term T cell
immunity is a major future goal. Applying emerging new
observations such as possible fate-determining signals
imprinted by early inflammatory cytokines or the asym-
metric separation of daughter T cells (Chang et al., 2007)
and other signals should empower and enhance vaccine
design. Moreover, the improved ability to implement402 Immunity 27, September 2007 ª2007 Elsevier Inc.functional genomic approaches and forward and reverse
genetics to study memory T cell differentiation should
provide rich opportunities to take our understanding of
effector and memory T cell differentiation to a new level
of practical application.
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